X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RP-1664 is a potential first-in-class, highly selective, PLK4 inhibitor. It is being developed for the treatment of adult and adolescent patients enriched for TRIM37-high solid tumors.
Lead Product(s): RP-1664
Therapeutic Area: Oncology Product Name: RP-1664
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Under the termination, Repare will regain global development and commercialization rights to RP-3500 (camonsertib), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase).
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,325.0 million Upfront Cash: $125.0 million
Deal Type: Termination February 12, 2024
Details:
Roche is responsible for the development and commercialization of RP-3500/RG6526 (camonsertib), a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene.
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: RG6526
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,338.6 million Upfront Cash: $125.0 million
Deal Type: Licensing Agreement January 25, 2024
Details:
The collaboration will explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class, selective and potent oral, small molecule inhibitor of PKMYT1 with anticancer activity.
Lead Product(s): Debio 0123,Lunresertib
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies. Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024.
Lead Product(s): RP-1664
Therapeutic Area: Oncology Product Name: RP-1664
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
RP-6306 (lunresertib) is a PKMYT1 inhibitor currently in Phase 1 clinical development a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche.
Lead Product(s): Lunresertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canadian Cancer Trials Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan.
Lead Product(s): RP-2119
Therapeutic Area: Oncology Product Name: RP-2119
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $175.0 million Upfront Cash: $15.0 million
Deal Type: Partnership January 19, 2023
Details:
Preclinical data demonstrated inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306 used CRISPR-based screening approach, to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.
Lead Product(s): RP-6306,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for treatment of solid tumors with specific genome instability related genomic alterations including those in the ATM (ataxia-telangiectasia mutated) gene.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
RP-3500, orally-administered ataxia telangiectasia and Rad3-related inhibitor currently in Phase 1/2 TRESR trial clinical development in patients with DNA damage repair, loss-of-function and mutant tumors.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
